首页> 外文OA文献 >In search of a tolerance-induction strategy for cow's milk allergies: significant reduction of beta-lactoglobulin allergenicity via transglutaminase/cysteine polymerization
【2h】

In search of a tolerance-induction strategy for cow's milk allergies: significant reduction of beta-lactoglobulin allergenicity via transglutaminase/cysteine polymerization

机译:寻找对牛奶过敏的耐受性诱导策略:通过转谷氨酰胺酶/半胱氨酸聚合反应显着降低β-乳球蛋白的致敏性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE: To explore the use of beta-lactoglobulin polymerized using microbial transglutaminase and heating to identify whether protein polymerization could reduce in vivo allergenicity and maintain in vitro and ex vivo immunoreactivity for use in tolerance-induction protocols. METHODS: Based on previous protocols applied in mice and children, we performed in vivo challenges (using a skin prick test) with native and polymerized beta-lactoglobulin in adult patients with an IgE-mediated allergy to beta-lactoglobulin. In vitro humoral immunoreactivity was analyzed using immunoblotting. Cell-mediated immunoreactivity was analyzed using ex vivo challenges with native and polymerized beta-lactoglobulin and monitored by leukocyte adherence inhibition tests. RESULTS: The skin tests demonstrated that there was a significant reduction in immediate cutaneous reactivity after polymerization. Polymerization did not decrease the immunoblotting detection of s-IgE specific to beta-lactoglobulin. Cell-mediated immunoreactivity, as assessed by ex vivo challenges and leukocyte adherence inhibition tests, did not exhibit significant differences between leukocytes challenged with native versus polymerized beta-lactoglobulin. CONCLUSIONS: The polymerization of beta-lactoglobulin decreased in vivo allergenicity and did not decrease in vitro humoral or ex vivo cell-mediated immunoreactivity. Therefore, we conclude that inducing polymerization using transglutaminase represents a promising technique to produce suitable molecules for the purpose of designing oral/sublingual tolerance induction protocols for the treatment of allergies.
机译:目的:探讨利用微生物转谷氨酰胺酶和加热聚合的β-乳球蛋白的用途,以鉴定蛋白质聚合是否可以降低体内过敏原性,并维持体外和离体免疫反应性,以用于耐受诱导方案。方法:基于先前在小鼠和儿童中应用的方案,我们对患有IgE介导的对β-乳球蛋白过敏的成年患者,使用天然和聚合的β-乳球蛋白进行了体内挑战(使用皮肤点刺试验)。使用免疫印迹分析体外体液免疫反应性。使用天然和聚合的β-乳球蛋白进行离体攻击,分析了细胞介导的免疫反应性,并通过白细胞粘附抑制试验进行了监测。结果:皮肤测试表明聚合后立即皮肤反应性明显降低。聚合反应不会降低对β-乳球蛋白特异的s-IgE的免疫印迹检测。通过离体攻击和白细胞粘附抑制测试评估的细胞介导的免疫反应性,在天然和聚合的β-乳球蛋白攻击的白细胞之间没有表现出显着差异。结论:β-乳球蛋白的聚合降低了体内的过敏原性,并没有降低体外的体液或离体细胞介导的免疫反应性。因此,我们得出结论,使用转谷氨酰胺酶诱导聚合反应代表了一种有前途的技术,可以产生合适的分子,以设计用于治疗变态反应的口服/舌下耐受诱导方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号